Chondrojoint for Germany
Waterbergh facilitated the partnering of Medevice, Turin, with Humantis, Cologne,
7 March, 2012 by
Chondrojoint for Germany
Waterbergh Management, Peter Kayatz

Product and Partners

ChondroJoint® is a polynucleotide gel for the treatment of painful joint diseases, to be injected directly into the joint.

Medevice is a wholly owned subsidiary of Medestea Internationale, based in Turin, Italy. Medevice is focusing on the research & development of medical devices.

Humantis is a wholly owned subsidiary of Medice, based in Cologne, Germany. Humantis is focusing on the distribution of private payer products to orthopedics.

Waterbergh’s engagement

  • Review, compilation, and revision of sales docs.

  • Identification of potential licensors in Germany.

  • Contact, management, and negotiation of the target companies.

  • Organization of management presentations.

  • Negotiation of the licensing term.

Waterbergh acted on behalf of the licensee Medevice, Turin, Italy.

Chondrojoint for Germany
Waterbergh Management, Peter Kayatz 7 March, 2012
Share this post
Our blogs